Repligen Stock Today
| RGEN Stock | USD 132.63 6.77 4.86% |
PerformanceWeakest
| Odds Of DistressLow
|
Repligen is selling at 132.63 as of the 13th of February 2026; that is 4.86% down since the beginning of the trading day. The stock's open price was 139.4. Repligen has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 15th of November 2025 and ending today, the 13th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 1990 | Category Healthcare | Classification Health Care |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. The company has 56.29 M outstanding shares of which 3.92 M shares are at this time shorted by private and institutional investors with about 6.44 trading days to cover. More on Repligen
Moving together with Repligen Stock
Moving against Repligen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Repligen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Anthony Hunt | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRepligen utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Repligen's leverage profile, showing how much of Repligen's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Repligen (RGEN) is traded on NASDAQ Exchange in USA and employs 1,778 people. Repligen is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.47 B. Repligen conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 56.29 M outstanding shares of which 3.92 M shares are at this time shorted by private and institutional investors with about 6.44 trading days to cover.
Repligen currently holds about 596.51 M in cash with 175.39 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.75.
Check Repligen Probability Of Bankruptcy
Ownership AllocationThe majority of Repligen outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Repligen to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Repligen. Please pay attention to any change in the institutional holdings of Repligen as this could imply that something significant has changed or is about to change at the company.
Check Repligen Ownership Details
Repligen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Brown Capital Management, Llc | 2025-06-30 | 1 M | |
| Geode Capital Management, Llc | 2025-06-30 | 980.7 K | |
| Conestoga Capital Advisors, Llc | 2025-06-30 | 976.9 K | |
| Holocene Advisors, Lp | 2025-06-30 | 936.8 K | |
| Alliancebernstein L.p. | 2025-06-30 | 906.4 K | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 768 K | |
| Impax Asset Management Group Plc | 2025-06-30 | 761 K | |
| Millennium Management Llc | 2025-06-30 | 701.2 K | |
| New York State Common Retirement Fund | 2025-06-30 | 606 K | |
| T. Rowe Price Associates, Inc. | 2025-06-30 | 6.6 M | |
| Blackrock Inc | 2025-06-30 | 6.1 M |
Repligen Historical Income Statement
Repligen Stock Against Markets
Repligen Corporate Management
| Christine Gebski | Senior Chromatography | Profile | |
| Kimberly Cornwell | General Counsel | Profile | |
| Dianne Heiler | Senior Sustainability | Profile | |
| James Bylund | Chief Officer | Profile | |
| Kola Otitoju | Senior Development | Profile | |
| Stephen Tingley | VP Sales | Profile | |
| Jaime Humara | Senior Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Life Sciences Tools & Services sector continue expanding? Could Repligen diversify its offerings? Factors like these will boost the valuation of Repligen. Anticipated expansion of Repligen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Repligen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.6 | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.219 | Return On Assets |
Investors evaluate Repligen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Repligen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Repligen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Repligen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Repligen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Repligen's market price signifies the transaction level at which participants voluntarily complete trades.